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Background: Recent studies showed a high frequency of low bone mineral density (BMD) in
HIV-infected patients and no reports have been issued in Turkey. Our aim was to evaluate
BMD  and risk factors for osteopenia/osteoporosis in HIV-infected patients that attended an
outpatient clinic in Istanbul, Turkey.
Method: In order to determine the prevalence of BMD, 126 HIV-infected patients had been
studied  with dual energy X-ray absorptiometry (DEXA). The association between BMD and
age,  gender, body mass index (BMI), habits, 25(OH)vitamin D, HIV RNA, CD4 lymphocyte
nadir,  using and duration of highly active antiretroviral treatment (HAART) were investigated
by  using multivariate analysis.
Results:  Median age was 40.1 years (range, 20–70); 84% were male; 35.7% patients had AIDS,
63.5%  were treated with HAART. Osteopenia and osteoporosis were  diagnosed in 53.9% and
23.8%, respectively. Mean plasma HIV RNA was 5.2 (SD 1.0) log10 copies/mL and CD4  lym-
phocyte  nadir was 313.8 (SD 226.2)/mm3. Factors associated with bone loss were high viral
load  (p = 0.034), using (p = 0.033) and duration of HAART (p = 0.008). No correlation had been
seen  between sex and osteopenia/osteoporosis (p = 0.794). However, males showed higher
rates  of osteoporosis than females (p = 0.042).Conclusions: Our results show a very high prevalence of bone mass reduction in Turkish HIV-
infected  patients. This study supports the importance of both HIV and antiretroviral therapy
in  low BMD.
been described in multiple studies and loss of bone min-
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDIV infected patients are now living longer with improved
uality of life, but have increased risk of chronic diseases
uch  as osteoporosis. The high prevalence of bone demineral-
zation  among younger and older HIV infected patients has
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eral  density (BMD) is associated with increased rates of bone
fractures.1,2 The most common fractures are those of the
vertebrae, hip and wrist. Management of hip fracture almost
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Table 1 – Proﬁles of studied HIV/AIDS patients.
n* Mean ± SD Minimum Maximum
Age 126 40.1 ± 11.3 20.0 70.0
Lombar spinal T-score
L2–L4
126  −0.9 ± 0.9 −3.3 2.2
Femur neck T-score 126 −1.6 ± 1.2 −4.3 2.4
BMI 126 24.9 ± 3.7 17.6 35.4
CD4+ cell count nadir 124 313.8 ± 226.2 5.0 1260.0
CD4+ cell count 120 440.9 ± 215.7 25.0 1260.0
5.2HIV RNA (log10 copies/mL) 93 
∗ Number of patients.
always require major surgical intervention and mortality rates
that can be as high as 30% in the ﬁrst year alone.3 Mortal-
ity  has also increased following vertebral fractures, which
cause  signiﬁcant complications including back pain, height
loss  and kyphosis. So, the early identiﬁcation and treatment of
osteopenia/osteoporosis is critical to protect the future health
of  HIV/AIDS patients.
There  are general effects of HIV infection that can be
risk  factors for low BMD.  These include low body mass
index  (BMI), physical inactivity, malabsorbtion (especially cal-
cium), hypogonadism, vitamin D deﬁciency, smoking, opiat
and  alcohol abuse. In addition to potential causes of osteope-
nia/osteoporosis the literature focuses on two causative
entities in HIV infection: the disease itself and its treatment.
It  is well known that BMD  values show differences
between populations. Prevalence and risk factors of osteope-
nia/osteoporosis in Turkish HIV-infected population have not
been  reported in the literature. Thus, in this study, our aim
was  to evaluate the BMD  and risk factors about osteope-
nia/osteoporosis among 126 HIV/AIDS patients who attended
our  outpatient clinic between June 2010 and May  2011, in Istan-
bul,  Turkey (latitude 41◦N).
Patients with known factors of osteopenia/osteoporosis
(hyperthyroidism, hyperparathyroidism, hypogonadism, dia-
betes mellitus, use of corticosteroids and menopause) had
been  excluded. None of them had received calcium and
vitamin  D supplement previously. We analyzed the relation
between  BMD  and age, gender, BMI, smoking (package/year),
alcoholism (three or more  drinks/day), illicit drug use
(months), antiretroviral treatment and duration (months), CD4
cell count nadir (/mm3), HIV viral load (copy/mL), blood cal-
cium,  phosphorus, iPTH, and 25(OH)vitamin D (nmol/mL)
determination. Data were  collected retrospectively from stan-
dardized HIV forms ﬁlled in at admission.
BMD was  measured in the posterior–anterior projection
at  the lumbar spine (L2–L4), at the left hip (femur neck,
trochanter and Wards  region) and of total body by DEXA (Nor-
land,  a CooperSurgical Company of Fort Atkinson, WI). DEXA
was  calibrated daily. All measurements were done by the same
qualiﬁed  technician. DEXA reported with T and Z-scores (T-
score  represents a SD of BMD  mean of the population at age
30,  Z-scores represents a SD of BMD  mean of the same age
and  sex group) was  performed in 126 HIV-infected patients.
The  patients were  diagnosed as normal, osteopenic (T-score
between  −2.5 and −1) and osteoporotic (T-score less than −2.5)
by  DEXA measurements and according to World Health Orga-
nization  criteria. ± 1.0 1.7 7.7
Total  plasma samples 25(OH)D was  measured by radioim-
munoassay (Diasorin). The 25(OH)D levels were  deemed
deﬁcient when <25 nmol/mL, insufﬁcient when 25–50 nmol,
sufﬁcient  when >50 nmol. BMI < 18.5 were  considered as
underweight, 18.5–24.9 as normal weight, 25–29.9 as over-
weight,  and 30≥ as obese. CD4 cell count was determined by
standard  ﬂow cytometry (FACScalibur, Becton Dickinson). Viral
load  was measured with the Cobas Amplicor HIV-1 (Roche). Bio-
chemical test levels were determined by automated standard
laboratory techniques.
All  analyses were performed by using SPSS version 13 soft-
ware.  Data were described using mean ± standard deviation
(SD)  (or median and range) and when indicated, as an abso-
lute  number and percentage. Chi-square test was  carried out
for  categorical data and Mann–Whitney-U test was used for
continuous  data. A p-value less than 0.05 was  considered sig-
niﬁcant.  Pearson correlation was used for continuous data for
investigating correlation. For this retrospective study, there
was  no need for ethical approval because all laboratory tests
carried  out were  part of the routine management of HIV-
infected  patients.
Table  1 shows analysis of the BMD, lombar spinal BMD,
femur  neck BMD, CD4+ cell count, CD4+ cell count nadir and
HIV  RNA level (log10 copies/mL) of 126 cases. Of these cases,
106  (84.1%) were male, 20 (15.9%) were female. Out of the total,
45  (35.7%) had AIDS, 80 (63.5%) were  treated with HAART.
DEXA  showed that the BMD of 77.7% (98/128) of the
patients was  decreased, 30 (23.8%) patients having osteoporo-
sis,  68 (53.9%) having osteopenia. Twenty-nine of the 106 male
patients  (27.4%) had osteoporosis, 53 (50%) had osteopenia.
One  (5%) of the 20 female patients had osteoporosis, 15 (75%)
had  osteopenia/osteoporosis. Grouping of patients according
to  sex, did not show any differences of low BMD  (p = 0.794).
However, males showed signiﬁcantly higher rates of osteo-
porosis  than females (p = 0.042).
Statistically, there was  no correlation between osteope-
nia/osteoporosis and age (p = 0.166). According to BMI  criteria,
75  (59.5%) patients had normal weight, 36 (28.6%) were  over-
weight,  14 (11.1%) were  obese, only 1 (0.8%) was  underweight.
One  (1%) of the 98 patients with the diagnosis of osteope-
nia/osteoporosis was  underweight, 60 (61.2%) had normal
weight,  26 (26.5%) were overweight, 11 (11.3%) were  obese. No
signiﬁcant relationship was  found between BMI and osteope-
nia/osteoporosis (p = 0.780).In  96 patients, 25(OH)D levels were  evaluated during the
period  of June 2010–October 2010, when exposure to direct
sunlight is at its highest levels. Of these patients, 79 (82%)
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Table 2 – Association between osteopenia/osteoporosis and duration of HAART.
BMD result Treatment duration Total
0–12 months 13–24 months 25–36 months 37–48 months
Normal
No 9 4 0 0 13
(%) (69.2) (30.8) (0) (0) (100)
Osteopenia/osteoporosis
No 25 16 11 15 67
(%) (37.3) (23.9) (16.4) (22.4) (100)
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(%) (42.5) (25) 
ere  males, median age was  40.1 years (range, 20–70). Four-
een  (14.6%) patients had deﬁcient, 66 (68.8%) had insufﬁcient
nd  16 (16.7%) had sufﬁcient levels. While the mean age of
eﬁcient/insufﬁcient patients is 40.04 ± 1.21, the mean age
f  sufﬁcient patients is 43.56 ± 3.19 and no correlation was
bserved  between age and vitamin D levels (p = 0.254). Seven
ut  of 17 female patients whose 25(OH)D levels were  evaluated
ad  veiled dressing style. We found the level of 25(OH)D signiﬁ-
antly  low in women  with veiled dressing style (17.0 ± 7.9 nmol
n  veiled and 33.9 ± 22.0 nmol in unveiled patients, p < 0.001).
wenty-two percent of BMD  normal cases and 15% of
steopenia/osteoporosis cases had normal 25(OH)D levels. No
elation between osteopenia/osteoporosis development and
5(OH)D  levels was  shown statistically by Mantel Haenzel
est  (p = 0.283). Among 19 patients who  were  not on HAART,
5(OH)D  levels were  deﬁcient in three (15.8%) and insufﬁ-
ient  in 14 (73.7%). Among 77 patients who used HAART,
5(OH)D levels were  found to be deﬁcient in 11 (14.3%),
nsufﬁcient in 52 (67.5%). Vitamin D levels were similar in
he  two groups. Smoking, heavy alcohol use and injection
rug  use were  not signiﬁcantly associated with osteope-
ia/osteoporosis (p = 0.09, p = 0.816, p = 0.724 respectively).
Statistical association between HIV RNA levels at ﬁrst
atient  admission and osteopenia/osteoporosis was  observed
p  = 0.034). Osteopenia/osteoporosis was  present in 37 of 45
f  patients with nadir CD4+ count of <200; 25 of 37 patients
ith  nadir CD4+ level of 200–350, and 34 of 42 patients with
adir  CD4+ level of >350. There was  no statistical differ-
nce  among these three groups (p = 0.229). Also, among 120
ases  in whom CD4+ count was  assessed before BMD  mea-
urement, osteopenia/osteoporosis was  present in 9 of 15
atients  with CD4+ count of <200, 19 of 24 patients with
00–350  and 66 of 81 patients with CD4+ count of >350. No
tatistical  signiﬁcance was  found among these three groups
p  = 0.097). Eighty of 126 patients (63.5%) were  treated with
AART.  Osteopenia/osteoporosis was  found in 67 (83.7%) of
he  80 cases using HAART, and 31 (67.3%) of 46 cases not
n  HAART (p = 0.033). Osteopenia/osteoporosis rate was sig-
iﬁcantly  associated with time elapsed on HAART (p = 0.008)
Table  2).
Osteopenia/osteoporosis development was  not associ-
ted  with the nucleoside reverse transcriptase inhibitors
NRTI) backbone, lamivudine + zidovudine or tenofonir
 emtricitabine (p = 0.106). Likewise, neither non-nucleoside
everse transcriptase inhibitors (NNRTI) or protease inhibitors11 15 80
(13.8) (18.8) (100)
(PI)  containing regimens was  associated with osteopenia/
osteoporosis (p = 0.365).
Osteopenia/osteoporosis may  be diagnosed before a frac-
ture  occurs by measuring BMD by DEXA. We evaluated BMD
of  HIV-infected patients using DEXA. Osteopenia and osteo-
porosis  were diagnosed in 53.9% and 23.8%, respectively.
Osteopenia rates varies from 24% to 59.5% and osteoporo-
sis  rates from 2% to 23% have been reported in HIV-infected
patients.4,5 Many studies have found higher rates of osteope-
nia/osteoporosis among male HIV-infected patients,6,7 in
contrast  to our study. Although females and males had a
similar  age range, males showed signiﬁcantly higher rates of
osteoporosis  than females.
Aging  is a well-established risk factor for reduced BMD  in
the  general population, as well as in HIV-infected patients.4,7
In our series, osteopenia/osteoporosis incidence was  non-
signiﬁcantly associated with age. Seventy-seven percent of our
patients, of whom 55.5% were in the range of 20–40 years of
age,  presented a decrease in BMD.
In many  studies, low BMI has emerged as an indepen-
dent risk factor for low BMD in HIV infected patients.4,7,8
Weight loss, wasting and malabsorbtion are associated with
HIV/AIDS.  Out of 126 patients 45 (35.7%) had AIDS, only one of
them  had low BMI, none of them had wasting syndrome. In
addition,  the HIV-infected population has high rates of smok-
ing,  alcohol abuse and illicit drug use, which are risk factors
for  low BMD. But these parameters have not accounted for the
higher  osteopenia/osteoporosis rate in our patients.
In  addition to immune regulation, vitamin D has the most
important role in calcium homeostosis and bone health.
Serum  25(OH)D levels reﬂect endogenously synthesized vita-
min  D and that obtained from the diet. Normal reference
values depend on factors such as sunlight exposure, season,
latitude,  skin pigmentation, age, and dietary vitamin D intake.
Istanbul  is located at 41◦N 28◦E where sufﬁcient sunlight is
available  to provide adequate ultraviolet B exposure between
June  and October. Thus, in order to assure statistical reliability
of  the study 25(OH)D levels of these 96 patients were  studied
during  the sunny season in Istanbul, Turkey. As a consequence
of  low sun exposure, in this study 25(OH)D level was  found
signiﬁcantly low in women with veiled dressing style. In HIV-
infected  patients, low 25(OH)D levels are likely a combination
of  both traditional risk factors and HIV-speciﬁc and HAART-
speciﬁc  contributors.9 Cozzolino et al. 10 demonstrated the
inhibition by PIs of the 25-hydroxylase and the 1-hydroxylase
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involved in vitamin D metabolism. Ellfolk et al. 11 showed
the  inhibition of the 25-hydroxylase by efavirenz. Vitamin D
deﬁciency and bone disease in HAART patients have been
associated with tenofovir and PIs.12 Vitamin D deﬁciency and
insufﬁciency  rates were  similar across different patient groups
using  and not using HAART. Rodriguez et al. 13 have found
25(OH)D deﬁciency in 10.5%, insufﬁciency in 36.8% among 57
unselected  HIV-infected outpatients. 25(OH)D deﬁciency rate
of our series was  similar to this study (14.6%), whereas insuf-
ﬁciency  rate was  twice more  often (68.8%).
The association between chronic inﬂammatory conditions
and  low BMD  is well documented and receptor activator of
NFkB  ligand (RANKL), the key mediator of osteoclast activity,
is  produced by activated T cells. In HIV infection, the virus can
infect  both activated T cells and macrophages. HIV-infected
activated T cells and osteoblasts produce RANKL, which fur-
ther  stimulates osteoclast activity. Speciﬁcally, HIV proteins
increase  osteoclastic activity and decrease bone formation by
promoting osteoblast apoptosis.14 Thus, many  studies showed
association between low BMD  and higher levels of HIV viremia
in  HAART naive patients.15,16 In our study, viral load level was
statistically higher in patients with osteopenia/osteoporosis
in line with other studies. However, Cazanave et al. 7 showed
that  low HIV viral load and low CD4+ lymphocyte nadir were
independent risk factors for low BMD,  suggesting an effect
of  therapy rather than the disease itself. On the other hand,
Collins17 had not found an association between abnormal
BMD  and CD4+ cell count nadir. In our study, there was  no
correlation  between either CD4+ cell count nadir or CD4+ cell
count  before BMD  measurement and osteopenia/osteoporosis.
Current knowledge suggests that both HIV and HAART are
likely  to contribute to osteopenia/osteoporosis in HIV-infected
patients. During antiretroviral therapy, especially at the begin-
ning,  there is an accelerated bone mineral loss associated with
bone  resorbtion markers. Immune reconstitution may  play a
role in early antiretroviral therapy-related bone loss. Initia-
tion  of HAART induces a marked loss of BMD (2–6%) within
the  ﬁrst two years, regardless of the initial choice of antiretro-
viral  therapy.18 In this study, it had been observed that, the
use  of HAART and the duration of therapy were  signiﬁcantly
related to osteopenia/osteoporosis. This ﬁnding could be due
to HAART use, but it also could be advanced HIV infection
necessitating HAART use. However, BMD  reduction with time
on therapy suggests the effect of HAART on bone density.
Many  authors indicate PIs as the responsible drug for low BMD,
whereas  others could not ﬁnd any difference among the vari-
ous  drugs used in HAART.4,12,19 Some PIs have been shown to
inhibit  osteogenesis and increase osteoclastogenesis. Among
the  NRTIs, of greatest interest for most clinicians, tenofovir
has  been the most frequently associated with bone loss. Teno-
fovir  may  affect bone indirectly through renal proximal tubule
toxicity,  resulting in phosphate wasting and increased bone
turnover.  Efavirenz and PIs may  affect BMD directly through
Vitamin  D metabolism.20 Patients in this research, used either
zidovudine/lamivudine or tenofovir/emtricitabine of the NRTI
group, lopinavir/r of the PI group, efavirenz of the NNRTI group.
There  was  no difference between drug groups in the sense of
osteopenia/osteoporosis development in this study.
The  two possible limitations of this study would be the
small  sample size and low heterogeneity of the patients. These
1 1 3;1  7(6):707–711
were unavoidable due to the small number of total HIV/AIDS
patients in Turkey.
In  conclusion, this study shows a very high prevalence of
bone  mass reduction in Turkish HIV-infected patients, espe-
cially  in young men. High viral load, use of HAART and
duration of therapy contributed to the increased prevalence
of  osteopenia/osteoporosis in our HIV infected population. It
is suggested that a monitoring of bone health should become
part  of routine care for all HIV-positive patients. With effective
treatments for osteopenia/osteoporosis available, it should be
possible to identify high-risk individuals and prevent fragility
fractures  in HIV-infected patients.
Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
 e  f  e  r  e  n  c  e  s
1. Arnsten JH, Freeman R, Ruth F, et al. Decreased bone mineral
density  and increased fracture risk in aging men with or at
risk  for HIV infection. AIDS. 2007;21:617–23.
2.  Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture
prevalence among human immunodeﬁciency virus
(HIV)-infected versus non-HIV-infected patients in a large U.S.
healthcare system. J Clin Endocrinol Metab. 2008;93:3499–504.
3. Brainsky A, Glick H, Lydick E, et al. The economic cost of hip
fractures  in community-dwelling older adults: a prospective
study. J Am Geriatr Soc. 1997;45:281–7.
4.  Bonjoch A, Figueras M, Estany C, et al. High prevalence of and
progression  to low bone mineral density in HIV-infected
patients: a longitudinal cohort study. AIDS. 2010;24:2827–33.
5. Brown TT, Ruppe MD, Kassner R, et al. Reduced bone mineral
density  in human immunodeﬁciency virus-infected patients
and  its association with increased central adiposity and
postload  hyperglicemia. J Clin Endocrinol Metab.
2004;89:1200–6.
6. Pinto Neto LF, Raqi-Eis S, Vieira NF, et al. Low bone mass
prevalence, therapy type, and clinical risk factors in an
HIV-infected Brazilian population. J Clin Densitom.
2011;14:434–9.
7. Cazanave C, Dupon M, Laviqnolle-Aurillac V, et al. Reduced
bone  mineral density in HIV-infected patients: prevalence
and  associated factors. AIDS. 2008;22:395–402.
8.  Jones S, Restrepo D, Kasowitz A, et al. Risk factors for
decreased bone density and effects of HIV on bone in the
elderly.  Osteoporos Int. 2008;19:913–8.
9.  Lake JE, Adams JS. Vitamin D in HIV-infected patients. Curr
HIV/AIDS  Rep. 2011;8:133–41.
0. Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE,
Dusso AS. HIV protease inhibitors impair vitamin D
bioactivation to 1,25-dihydroxyvitamin D. AIDS.
2003;17:513–20.
1. Ellfolk M, Norlin M, Gyllensten K, Wikvall K. Regulation of
human  vitamin D(3) 25-hydroxylases in dermal ﬁbroblasts
and  prostate cancer LNCaP cells. Mol Pharmacol.
2009;75:1392–9.
2. Brown TT, Qaqish RB. Antiretroviral therapy and the
prevalence of osteopenia andosteoporosis: a meta-analytic3. Rodriguez M, Daniels B, Gunawardene S, Robbins GK. High
frequency of vitamin D deﬁciency in ambulatory HIV-positive
patients. AIDS Res Hum Retroviruses. 2009;25:9–14.
 2 0 1 
1
1
1
1
1
1
syndrome-extended followup to 48 weeks. Antivir Ther.
2000;5:42.b r a z j i n f e c t d i s .
4. Fakruddin JM, Laurence J. HIV envelope gp120-mediated
regulation of osteoclastogenesis via receptor activator of
nuclear  factor kappa B ligand (RANKL) secretion and its
modulation by certain HIV protease inhibitors through
interferon-gamma/RANKL cross-talk. J Biol Chem.
2003;278:48251–8.
5. Lawal A, Engelson ES, Wang J, Heymsﬁeld SB, Kotler DP.
Equivalent osteopenia in HIV-infected individuals studied
before  and during the era of highly active antiretroviral
therapy. AIDS. 2001;15:278–80.
6. Knobel H, Guelar A, Valecillo G, Nogues X, Diez A. Osteopenia
in  HIV-infected patients: is it the disease or is it the
treatment. AIDS. 2001;15:807–8.
7. Collins S. High rates of osteopenia and osteoporosis:
importance of DEXA monitoring. In: HIV treatment Bulletin,
23;1 7(6):707–711  711
June 2010. 2nd Joint conference of the BHIVA and BASHH.
2010.
8. Brown TT, McComsey GA, King MS, Qadish RB, Bernstein BM,
da  Silva BA. Loss of bone mineral density after antiretroviral
therapy initiation, independent of antiretroviral regimen. J
Acquir  Immune Deﬁc Syndr. 2009;51:554–61.
9.  Hoy J, Hudson J, Law M, Cooper DA. Osteopenia in a
randomized, multicentre study of protease inhibitor
substitution in patients with the lipodystrophy0. Fabbriciani G, De Socio GV. Efavirenz and bone health. AIDS.
2009;23:1181.
